Expert review of clinical immunology | 13 Jan 2018
L Seale, LA Cardwell and SR Feldman
Psoriasis has a profound impact on patients' lives, but adherence to topical treatment of psoriasis is still poor. Biologic treatment has revolutionized the management of psoriasis, but adherence to treatment may still be a barrier for some patients. Areas covered: A PubMed search was conducted in August 2017 using the terms “biologics psoriasis adherence” and “biologics psoriasis survival.” Additional articles were obtained by perusing the references of articles identified in the original PubMed search. Articles that did not specifically mention “survival,” “adherence,” or “persistence” were not included. We review the measures used to assess adherence to biologics for psoriasis and the factors impacting drug survival and adherence rates for biologics in psoriasis. Expert commentary: Drug survival and adherence rates for biologic therapy is less than ideal but may be modifiable. Means that may improve adherence and drug survival include individualized choice of biologic and providing additional support for patients who are at increased risk for prematurely stopping treatment.
* Data courtesy of Altmetric.com